About us Pricing ContactSubscribe

P

Paul Depledge

Institute of Cancer Research

h-index

—

Publications

—

Citations

—

i10-index

—

Impact (2-yr)

—

Top Publications

The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

Journal of Medicinal Chemistry2008741 citations

Paul Depledge · Scinovex